GSK reaches confidential settlement with James Goetz in Zantac litigation

GSK

GSK plc (LON/NYSE: GSK) today confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July 24, 2023, will be dismissed.

The settlement reflects the Company’s desire to avoid distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.

Share on:

Latest Company News

GSK reports 5% Q3 sales growth and reaffirms 2026 guidance

GSK reported third-quarter sales of £8.9 billion, up 5% at constant exchange rates, driven by 15% growth in Specialty...

GSK reports 62% response rate in ovarian cancer trial

GSK has reported a confirmed response rate of 62% for its investigational drug mocertatug rezetecan in patients with platinum-resistant...

GSK wins FDA approval for hepatitis B treatment Hibsago

GSK has received FDA approval for Hibsago (bepirovirsen), a new chronic hepatitis B treatment that achieved a 19% functional...

GSK reports positive global results for lung cancer drug candidate

GSK reports first global data for investigational antibody-drug conjugate risvutatug rezetecan, showing a confirmed objective response rate of 61%...

GSK to acquire Chimagen Trispecific T-cell engager for multiple myeloma

GSK has agreed to acquire global rights to Chimagen Biosciences’ trispecific T-cell engager for multiple myeloma in a deal...

GSK’s Shingrix prefilled syringe approved in Japan

Japan’s health ministry has approved a ready-to-use prefilled syringe presentation of GSK’s Shingrix shingles vaccine, simplifying preparation and administration...

    Search